Announcements Trials
Browse Landscape

Phase

Phase 1 28Phase 2 23Phase 1/2 11Phase 3 7Phase NA 3Phase EARLY_PHASE1 2Phase 2/3 2Phase 4 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioblastoma 2Carcinoma 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Stage I Prostate Adenocarcinoma AJCC v7 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Perivascular Epithelioid Cell Neoplasms 1Oropharyngeal Neoplasms 1Oligodendroglioma 1Neurofibrosarcoma 1Nerve Sheath Neoplasms 1Mucositis 1Mouth Neoplasms 1Lymphoma 1Lung Neoplasms 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Histiocytoma, Angiomatoid Fibrous 1Head and Neck Neoplasms 1Granuloma, Plasma Cell 1Gliosarcoma 1Fibrosarcoma 1

Interventions

Temozolomide 8Lomustine 4vocimagene amiretrorepvec 2Radiation 2veliparib 1tinostamustine 1regorafenib 1carbon-11 acetate 1antisecretory factor 1Sunitinib 1Standard of Care 1Radiotherapy 1Magnetic Resonance Spectroscopy 1Irinotecan 1GDC-0084 1Flucytosine 1Etoposide 1Drug Therapy 1Disulfiram 1Dianhydrogalactitol 1DNA 1Copper 1Carbon-11 1Bevacizumab 1Alkylating Agents 1AZD1390 1ADI PEG20 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Glioblastoma × Radiation × Clear all
NCT03970447 2026-05-15

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting
2,250 enrolled
CNS

Glioblastoma, Recurrence

NCT04105374 2026-05-07

Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma

NRG Oncology

Phase 2/3 Withdrawn
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡